United States Uterine Fibroid Market – Overview

The United States Uterine Fibroid market is showing the significant growth; mainly due to change in lifestyle mainly dietary pattern, growing number of hysterectomy surgeries. Additionally rising in aging population also leads the Uterine Fibroid market with in this region. According to U.S. Department of Health and Human Services, study found that before 50s 70% of white and 80% of African Americans are diagnosed with fibroids. Also more than 200,000 hysterectomies are performed each year for uterine fibroids. Hysterectomies is the surgery that is used to remove the uterus, if the condition is painful.

Request for Sample Report at www.marketresearchfuture.com/sample_request/2394

Increasing incidence of uterine fibroid United States generate the interest of companies toward the market of uterine fibroid, as they feel there are huge opportunities and gaps between the market demand and supply of quality devices.

Thus, companies are showing more interest in research and development activities for introducing the advanced treatment that meets the requirement of market. For instant, in Feb 2017, AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada.

Top players:

AstraZeneca

Cook Medical

Boston Scientific Corporation

GE Healthcare

AbbVie

Hologic

CooperSurgical

C. R. Bard

And more.

Segments:

U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners, Computed tomography (CT), Ultrasounds and others. On the basis of treatment the market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.


Uterine Fibroid Market – Regional Analysis

The market of Uterine Fibroid devices is much higher in the United States region, owing to its high prevalence in African- American race, change in lifestyle. According to one large cohort study of NIS on African-American women in Maryland, uterine fibroids was the cause of 65.4% of total 53,000 women undergoing hysterectomy.

Moreover, most of the major market players belong from this region, thus they introduce the advance technology firstly in the United States in comparison to others region. Additionally the market players of this region also involve in export of Uterine Fibroid devices in the developing regions of Asia Pacific for meeting the unmet needs.

Also Government of developing countries are willing to adopt advanced treatment option available in developed countries, in order to improve the quality of life of their citizen, which fuel the market of Uterine Fibroid devices. Countries like India and China are more focused market for United States market players owing to the huge patient population and growing purchasing power as compare to other countries in this region. Thus the players belong from the United States have opportunity of increase the market share and maximize the profit by exporting to these nation.

Major TOC of Uterine Fibroid Market Research Report - U.S. Forecast to 2022

1 Introduction

2 Scope of Study

3 Research Methodology

4 U.S. Uterine Fibroid Market

5 Company Profile

Browse Complete 47 Pages Premium Research Report Enabled with 38 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394


About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]